Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal CancerAntonio Avallone, Alfredo Budillon, Valeria Vicario et al.|JAMA Network Open|2021Cited by 34
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The IMPROVE TrialAntonio Avallone, Alfredo Budillon, Francesco Giuliani et al.|Journal of Clinical Oncology|2024Cited by 14
Fluoropyrimidines in the Treatment of Advanced Neoplastic Diseases: Role and Advantages of UFTMichele Del Vecchio, Emilio Bajetta, Giuseppe Procopio et al.|Tumori Journal|1999Cited by 8
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II studyClaudia Cardone, Antonio Avallone, Alfonso De Stefano et al.|ESMO Open|2023Cited by 6
Update survival analysis from a multicenter, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC).Antonio Avallone, Maria Carmela Piccirillo, Guglielmo Nasti et al.|Journal of Clinical Oncology|2018Cited by 1